$68.85
3.75%
NYSE, Apr 21, 08:45 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$71.53
+0.90 1.27% 1M
+3.06 4.47% 6M
-2.50 3.38% YTD
-15.71 18.01% 1Y
-47.75 40.03% 3Y
-4.61 6.05% 5Y
+48.21 206.69% 10Y
NYSE, Closing price Thu, Apr 17 2025
+0.33 0.46%
ISIN
US28176E1082
Symbol
EW
Sector

Key metrics

Market capitalization $41.90b
Enterprise Value $38.68b
P/E (TTM) P/E ratio 29.20
EV/FCF (TTM) EV/FCF 133.44
EV/Sales (TTM) EV/Sales 6.76
P/S ratio (TTM) P/S ratio 7.32
P/B ratio (TTM) P/B ratio 4.21
Revenue growth (TTM) Revenue growth -4.67%
Revenue (TTM) Revenue $5.72b
EBIT (operating result TTM) EBIT $1.53b
Free Cash Flow (TTM) Free Cash Flow $289.90m
Cash position $3.98b
EPS (TTM) EPS $2.45
P/E forward 29.77
P/S forward 7.20
EV/Sales forward 6.65
Short interest 1.85%
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

15x Buy
47%
16x Hold
50%
1x Sell
3%

Analyst Opinions

32 Analysts have issued a Edwards Lifesciences forecast:

Buy
47%
Hold
50%
Sell
3%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5,724 5,724
5% 5%
100%
- Direct Costs 1,262 1,262
12% 12%
22%
4,463 4,463
2% 2%
78%
- Selling and Administrative Expenses 1,698 1,698
2% 2%
30%
- Research and Development Expense 1,082 1,082
1% 1%
19%
1,682 1,682
8% 8%
29%
- Depreciation and Amortization 155 155
2% 2%
3%
EBIT (Operating Income) EBIT 1,527 1,527
9% 9%
27%
Net Profit 1,467 1,467
5% 5%
26%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Business Wire
3 days ago
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in heart valve innovations....
Neutral
Business Wire
5 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and ...
Neutral
Business Wire
7 days ago
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the company's SAPI...
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today